Leflunomide use in renal transplantation

Current Opinion in Organ Transplantation

Volumn 14, Issue 4, 2009, Pages 370-374

  Leca, Nicolae ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

BK nephropathy; Leflunomide; Renal transplantation

Indexed keywords

A 77 1726; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; TACROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; DRUG EFFECT; DRUG INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MALAISE; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NEUROPATHY; PNEUMONIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIVIRAL AGENTS; BK VIRUS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY TRANSPLANTATION; POLYOMAVIRUS INFECTIONS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 68849120249     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832dbc48     Document Type: Review

References (39)

1. Ostensen M. Disease specific problems related to drug therapy in pregnancy. Lupus 2004; 13:746-750. (Pubitemid 39279796)
2. Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004; 117:87-92. (Pubitemid 38953727)
3. Curtis J, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 2009. [Epub ahead of print]
4. Cannon G, Kremer J. Leflunomide. Rheum Dis Clin North Am 2004; 30:295-309.
5. Chikura B, Lane S, Dawson J. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009. [Epub ahead of print]
6. Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007; 14:179-181.
7. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352:1157-1158.
8. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 81: 704-710.
9. Hirsch H, Brennan D, Drachenberg C, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79:1277-1286. (Pubitemid 40734783)
10. Leca N, Muczynski K, Jefferson J, et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol 2008; 3:829-835.
11. McChesney L, Xiao F, Sankary H, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57:1717-1722. (Pubitemid 24206409)
12. Shawver L, Schwartz D, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3:1167-1177. (Pubitemid 27319763)
13. Waldman W, Bickerstaff A, Gordillo G, et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 72:1578-1582. (Pubitemid 33095519)
14. Faguer S, Hirsch H, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007; 20:962-969. (Pubitemid 47537566)
15. Farasati N, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005; 79:116-118. (Pubitemid 40140009)
16. Randhawa P. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis 2005; 41:1366-1367.
17. Drachenberg C, Hirsch H, Ramos E, Papadimitriou J. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol 2005; 36:1245-1255. (Pubitemid 41682279)
18. Mannon R, Hoffmann S, Kampen R, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005; 5:2883-2893.
19. Muñoz Garcia P. BK Virus in Liver Transplant Recipients: a Prospective Study. Transplant Proc 2009; 41 (3):1033-1037.
20. Wong A, Cheng V, Yuen K, et al. High frequency of polyoma BK virus shedding in the gastrointestinal tract after hematopoietic stem cell transplantation: a prospective and quantitative analysis. Bone Marrow Transplant 2009; 43:43.
21. Williamson RA, Yea CM, Robson PA, et al. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc 1996; 28:3088-3091.
22. Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995; 44:317-322.
23. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50:861-867.
24. Xu X, Williams JW, Bremer EG, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270:12398.
25. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159:22-27.
26. Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160:1581-1588. (Pubitemid 28106441)
27. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162 (4):2095-2102.
28. Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42 (5-6):412-418. (Pubitemid 30122078)
29. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68:814-825. (Pubitemid 29468200)
30. Chong A, Zeng H, Knight D, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6: 69-75. (Pubitemid 43382202)
31. Knight D, Hejmanowski A, Dierksheide J, et al. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71:170-174. (Pubitemid 32105800)
32. John G, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 2004; 77:1460-1461. (Pubitemid 38668445)
33. Avery R. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis 2008; 21:433-437.
34. Limaye A. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35:866-872.
35. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223-1231.
36. Swan SK, Crary GS, Guijarro C, et al. Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Transplantation 1995; 60:887.
37. Hardinger KL, Wang CD, Schnitzler MA, et al. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2002; 2:867-871.
38. Chong A, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999; 68:100-109.
39. Leca N, Kendrick E, Jefferson A, et al. Leflunomide effect on the titers of donor specific antibodies in chronic antibody mediated rejection. Am J Transplant 2008; 8 (Suppl 2):136.